Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
C'est le cas dans une étude menée depuis trois ans à l'Institut Gladstone: les chercheurs ont découvert qu'un médicament contre l'épilepsie réduit, entre autres, la perte de mémoire, principale conséquence de la maladie d'Alzheimer.
In an animal model of the disease, scientists at the University of California, San Francisco-affiliated Gladstone Institutes have discovered that Levetiracetam - an FDA-approved drug commonly prescribed for patients who suffer from epilepsy, reverses memory loss and alleviates other Alzheimer's-related impairments.
Un antiépileptique pourrait bien rétablir la mémoire dans la maladie d'Alzheimer, selon cette étude du Gladstone Institutes, soutenue, entre autres institutions par les National Institutes of Health.
A drug that already curbs epileptic seizures could be used to reverse memory loss and other brain functions in some Alzheimer's disease patients, researchers at the Gladstone Institutes discovered.
Scientists in the laboratory of Lennart Mucke, MD discovered that the FDA-approved anti-epileptic drug levetiracetam restores memory function in mice genetically modified to simulate key aspects of Alzheimer's disease.
Topping this year’s survey of academic researchers is the Gladstone Institutes, a San Francisco-based nonprofit biomedical research organization with a focus on cardiovascular disease, virology and immunology, and neurodegenerative disorders that also won the top honors last year.
Topping this year’s survey of academic researchers is the J. David Gladstone Institutes, a San Francisco-based nonprofit biomedical research organization with a focus on cardiovascular disease, virology and immunology, and neurodegenerative disorders that also won the top honors last year
A couple of small West Coast research centers, the J. David Gladstone Research Institutes in San Francisco, and Sage Bionetworks in Seattle, have gotten kudos as the “Best Places to Work” in academia by The Scientist magazine.
An astonishing discovery by Deepak Srivastava and his team at the Gladstone Institutes offers hope that heart damage may one day be reversible.
The Gladstone Institutes now belong to Sandy Williams. Science, fundraising and operations are locked into Williams’ vision nearly two years after he started remaking the 33-year-old San Francisco biomedical research organization as only its second president.